ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2325 • 2014 ACR/ARHP Annual Meeting

    A Systematic Review of the Educational Approach of Occupational Therapy for Rheumatoid Arthritis

    Kristine Carandang and Elizabeth Pyatak, Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA

    Background/Purpose: In order to enhance daily functioning for patients with chronic conditions, occupational therapists employ a range of techniques and strategies. Among these strategies, interventions…
  • Abstract Number: 2326 • 2014 ACR/ARHP Annual Meeting

    Investigation of Parameters Used to Test Quadriceps Muscle Power Using Isokinetic Dynamometer in Arthritis

    Maria Beatriz Catelani1, Samannaaz S. Khoja2, Gustavo J. Almeida2 and Sara R. Piva1, 1Physical Therapy, University of Pittsburgh, Pittsburgh, PA, 2Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose Muscle power (MP) plays an important role in daily activities that require force generated at fast speeds such as climbing stairs. MP is decreased…
  • Abstract Number: 2327 • 2014 ACR/ARHP Annual Meeting

    Delivering ESCAPE-Pain (Enabling Self-Management and Coping of Arthritic Pain through Exercise ) – an Online Guide for Healthcare Professionals

    Michael V. Hurley1,2, Andrea Carter2, Des Carter2, Lonan Hughes3, Aoife Ni Mhuiri4,5 and Nicola E. Walsh6, 1School of Rehabilitation Sciences, St George's University of London and Kingston University, London, United Kingdom, 2Musculoskeletal Programme, Health Innovation Network South London, London, United Kingdom, 3Research & Development, Salaso Health Solutions, Tralee, Ireland, 4Salaso Health Solutions, Tralee, Ireland, 5Institute of Technology Tralee, Tralee, Ireland, 6Allied Health Professions, University of the West of England Bristol, Bristol, United Kingdom

    Background/Purpose: Worldwide, chronic joint pain is a major cause of suffering, impaired mobility, physical and psychosocial function, quality of life, dependency and healthcare expenditure. Enabling…
  • Abstract Number: 2328 • 2014 ACR/ARHP Annual Meeting

    The Physical and Psychosocial Effects of Exercise on Chronic Hip and Knee Pain: A Cochrane Review with Meta-Analysis

    Professor Mike Hurley1, Dr Nicola E. Walsh2, Sandy Oliver3, Hanan Hauari3, Kelly Dickson4, Robert Grant5 and Jo Cumming6, 1School of Rehabilitation Sciences, St George's University of London and Kingston University, London, United Kingdom, 2Allied Health Professions, University of the West of England, Bristol, United Kingdom, 3Social Science Research Unit, Institute of Education University of London, London, United Kingdom, 4Social Science Research Unit, Institute of education University of London, London, United Kingdom, 5Faculty of Health, Social Care and Education, St George's University of London and Kingston University, London, United Kingdom, 6Information, Arthritis Care, London, United Kingdom

    Background/Purpose: Chronic peripheral joint pain is extremely prevalent and a major cause of physical and psychosocial problems. Exercise improves pain and physical function, but the…
  • Abstract Number: 2329 • 2014 ACR/ARHP Annual Meeting

    Course and Outcome of Rehabilitation Care in Different Rheumatological Diagnosis Groups. a Descriptive Study Using the STAR-Etic Registry

    Elisabet Lindqvist1, Margreth Grotle2, Kim Hoerslev-Petersen3, Theodora P.M. Vliet Vlieland4 and Ann B. I. Bremander5, 1Department of Clinical Sciences, Lund, Section for Rheumatology, Lund, Lund University and Skåne University Hospital, Lund, Sweden, 2Rheumatology, National Resource Centre for Rehabilitation in Rheumatology, Diakonhjemmet Hospital, N-0319 Oslo, Norway, 3Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, 4Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands, 5Spenshult Research and Development Center, Halmstad, Sweden

    Background/Purpose: The frequency of admission to rehabilitation varies among countries but also among diagnosis groups. So far research describing and comparing the rehabilitation in various…
  • Abstract Number: 2330 • 2014 ACR/ARHP Annual Meeting

    Construct Validity of the Adult Myopathy Assessment Tool in Individuals with Inclusion Body Myositis

    Michael Harris-Love1, Galen Joe2, Todd Davenport3, Joseph Shrader2, Beverly McElroy4, Goran Rakocevic5, Olavo Vasconcelos6 and Marinos Dalakas5, 1Geriatrics Service, VA Medical Ctr, Washington, DC, 2Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD, 3Department of Physical Therapy, University of the Pacific, Stockton, CA, 4National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 5Department of Neurology, Thomas Jefferson University, Philadelphia, PA, 6Department of Neurology, Richmond Veterans Affairs Medical Center, Richmond, VA

    Background/Purpose The Adult Myopathy Assessment Tool (AMAT) is a 13-item performance-based battery developed to assess function and anaerobic endurance in adults with muscle disease.  The…
  • Abstract Number: 2331 • 2014 ACR/ARHP Annual Meeting

    People’s Views, Beliefs and Experiences of Exercise for Chronic Hip and Knee Pain: Cochrane Review with Qualitative Synthesis

    Professor Mike Hurley1, Kelly Dickson2, Hanan Hauari3, Dr Nicola E. Walsh4, Robert Grant5, Jo Cumming6 and Sandy Oliver3, 1School of Rehabilitation Sciences, St George's University of London and Kingston University, London, United Kingdom, 2Social Science Research Unit, Institute of education University of London, London, United Kingdom, 3Social Science Research Unit, Institute of Education University of London, London, United Kingdom, 4Allied Health Professions, University of the West of England, Bristol, United Kingdom, 5Faculty of Health, Social Care and Education, St George's University of London and Kingston University, London, United Kingdom, 6Information, Arthritis Care, London, United Kingdom

    Background/Purpose: Chronic peripheral joint pain is extremely prevalent and a major cause of physical and psychosocial dysfunction. Exercise improves pain and physical function, but the…
  • Abstract Number: 2332 • 2014 ACR/ARHP Annual Meeting

    Use of Wrist Hand Orthoses during Hand Function Skills and Functional Tasks By Adults with and without Rheumatoid Arthritis

    Janet L. Poole1, Kelly Nunez2 and Patricia Burtner3, 1Occupational Therapy Program, University of New Mexico, Albuquerque, NM, 2Occupational Therapy, Veteran's Administration Medical Center, Albuquerque, NM, 3Occupational Therapy, University of New Mexico, Greenbank, WA

    Background/Purpose : To determine changes in muscle activation in the upper extremity using electromyography (EMG) when static and dynamic orthoses are worn by adults with and…
  • Abstract Number: 2292 • 2014 ACR/ARHP Annual Meeting

    Demographic, Clinical and Treatment Characteristics of the Childhood Arthritis and Rheumatology Research Alliance Registry Systemic JIA Cohort

    Ginger L. Janow1, Laura Schanberg2, Soko Setoguchi3, Elizabeth D. Mellins4, Rayfel Schneider5, Yukiko Kimura1,6 and The CARRA Registry Investigators7, 1Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, 2Duke University, Durham, NC, 3Duke Clinical Research Institute, Durham, NC, 4Dept of Pediatrics CCSR, Stanford University Medical Center, Stanford, CA, 5Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 6Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, 7Childhood Arthritis and Rheumatology Research Alliance, Durham, NC

    Background/Purpose: Systemic JIA (sJIA) is a rare disease whose treatment has changed in the past 10 yrs. The Childhood Arthritis and Rheumatology Research Alliance (CARRA)…
  • Abstract Number: 2293 • 2014 ACR/ARHP Annual Meeting

    Preliminary Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study

    Yukiko Kimura1, Esi Morgan-DeWitt2, Kelly L. Mieszkalski3, Thomas Brent Graham4, Timothy Beukelman5, Maria F. Ibarra6, Norman T. Ilowite7, Marisa S. Klein-Gitelman8, Karen Onel9, Sampath Prahalad10, Marilynn G. Punaro11, Sarah Ringold12, Dana Toib13, Heather Van Mater14, Pamela F. Weiss15 and Laura Schanberg16, 1Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, 2Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Dept of Pediatrics, Duke University Medical Center, Durham, NC, 4Pediatric Rheumatology, Vanderbilt Children's Hospital, Nashville, TN, 5Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, 7Pediatrics, Albert Einstein College of Medicine, Bronx, NY, 8Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 9Division of Pediatric Rheumatology, University of Chicago, Chicago, IL, 10Emory University School of Medicine, Atlanta, GA, 11Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, 12Seattle Children's Hospital, Seattle, WA, 13St. Christopher's Hospital for Children, Philadelphia, PA, 14Duke Pediatric Rheumatology, Duke University Medical Center, Hillsborough, NC, 15Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, 16Duke University, Durham, NC

    Background/Purpose: Treatment options for systemic JIA (sJIA) have recently expanded to include IL1 and IL6 inhibitors in addition to traditional treatments such as glucocorticoids (GC)…
  • Abstract Number: 2294 • 2014 ACR/ARHP Annual Meeting

    The Presentation and Initial Treatment of Systemic Juvenile Idiopathic Arthritis According to Observational Data from the United States and the United Kingdom

    Timothy Beukelman1, Roberto Carrasco2, Yukiko Kimura3, Laura Schanberg4, Wendy Thomson5, Kimme L. Hyrich6, For the CARRA Registry Investigators7 and For the CAPS Investigators Group8, 1Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 3Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, 4Duke University, Durham, NC, 5Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 6Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 7CARRA, Durham, NC, 8CAPS, Manchester, United Kingdom

    Background/Purpose: Systemic JIA (sJIA) treatment has changed dramatically with the introduction of biologic agents, although treatment approaches may differ between countries. We characterized and compared…
  • Abstract Number: 2295 • 2014 ACR/ARHP Annual Meeting

    A Pharmacometric Based Analysis of the Occurrence of Selected Safety Events of Special Interest and Canakinumab Exposure in Systemic Juvenile Idiopathic Arthritis Patients

    Micha Levi1, Thomas Dumortier2, Nicolino Ruperto3, Hermine H. Brunner4 and Olivier Luttringer2, 1Novartis Pharmaceutical Corporation, East Hanover, NJ, 2Novartis Pharma AG, Basel, Switzerland, 3Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, 4Rheumatology, PRCSG-Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose Canakinumab (CAN), a human, selective anti-interleukin-1β monoclonal antibody, has demonstrated rapid and sustained efficacy in systemic juvenile idiopathic arthritis (SJIA) patients,1and is approved in…
  • Abstract Number: 2296 • 2014 ACR/ARHP Annual Meeting

    Tocilizumab Therapy in Children with Systemic Juvenile Idiopathic Arthritis. DATA from Russian Register of Sjia

    Ekaterina Alexeeva1,2, Saniya Valieva1, Rina Denisova1, Tatyana Bzarova1, Kseniya Isayeva1, Tatyana Sleptsova1, Elena Mitenko1, Evgeniya Chistyakova1,2, Anna Fetisova1 and Olga Lomakina3, 1Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, 2I.M.Sechenov First Moscow State Medical University, Moscow, Russia, 3Scientific Center of Children's Health of RAMS, Moscow, Russia

    Background/Purpose Systemic Juvenile Idiopathic Arthritis (sJIA) is classified as an acquired autoinflammatory disease. The interleukin-1 and interleukin-6 play a pivotal role in pathogenesis of this…
  • Abstract Number: 2297 • 2014 ACR/ARHP Annual Meeting

    Efficacy of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) using JADAS Criteria – an Analysis of 12-Week Pooled Data

    A. Ravelli1, H. I. Brunner2, N. Ruperto1, P. Quartier3, A. Consolaro4, N.M. Wulffraat5, K. Lheritier6, C. Gaillez6, A. Martini1 and D.J. Lovell2, 1PRINTO-Istituto Gaslini, Genova, Italy, 2PRCSG, Cincinnati, OH, 3Necker-Enfants Malades Hospital, Paris, France, 4Pediatria II, PRINTO-Istituto Gaslini, Genova, Italy, 5UMC Utrecht, Utrecht, Netherlands, 6Novartis Pharma AG, Basel, Switzerland

    Background/Purpose Chronic active disease and persistent synovial inflammation can lead to structural damage, joint destruction and impairment of physical function in patients with systemic juvenile…
  • Abstract Number: 2298 • 2014 ACR/ARHP Annual Meeting

    Canakinumab Treatment Shows Maintained Efficacy in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Individual Patient Level: An Analysis of 12 Week Pooled Data

    A. Ravelli1, H.I. Brunner2, N. Ruperto1, P. Quartier3, A. Consolaro1, N.M. Wulffraat4, K. Lheritier5, C. Gaillez5, A. Martini1 and D.J. Lovell2, 1Istituto Gaslini-PRINTO, Genova, Italy, 2PRCSG, Cincinnati, OH, 3Necker-Enfant Malades Hospital, Paris, France, 4UMC Utrecht, Utrecht, Netherlands, 5Novartis Pharma AG, Basel, Switzerland

    Background/Purpose Key objectives of biologic therapies in systemic juvenile idiopathic arthritis (SJIA) are to induce and maintain inactive disease, according to the ACR 2011 definition.…
  • « Previous Page
  • 1
  • …
  • 1896
  • 1897
  • 1898
  • 1899
  • 1900
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology